Cambiar Investors’s Haemonetics HAE Stock Holding History

Cambiar Investors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-25,030	Closed	-$906K	–	163
2016 Q3	$906K	Hold	25,030	–	–	0.01%	146
2016 Q2	$726K	Sell	25,030 -952,363	-97%	-$28.8M	0.01%	135
2016 Q1	$34.2M	Sell	977,393 -31,182	-3%	-$1.01M	0.49%	63
2015 Q4	$32.5M	Buy	1,008,575 +41,988	+4%	+$1.36M	0.47%	74
2015 Q3	$31.2M	Buy	966,587 +4,844	+0.5%	+$182K	0.46%	89
2015 Q2	$39.8M	Sell	961,743 -7,078	-0.7%	-$298K	0.56%	84
2015 Q1	$43.5M	Sell	968,821 -156,801	-14%	-$6.55M	0.63%	64
2014 Q4	$42.1M	Sell	1,125,622 -14,819	-1%	-$543K	0.64%	73
2014 Q3	$39.8M	Sell	1,140,441 -5,930	-0.5%	-$212K	0.57%	85
2014 Q2	$40.4M	Buy	1,146,371 +32,698	+3%	+$1.09M	0.57%	82
2014 Q1	$36.3M	Buy	1,113,673 +92,968	+9%	+$3.55M	0.54%	84
2013 Q4	$43M	Buy	1,020,705 +12,480	+1%	+$514K	0.63%	64
2013 Q3	$40.2M	Buy	+1,008,225	New	+$42.3M	0.66%	68

Other funds holding HAE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cambiar Investors's HAE Position: Q4 2016 in Review

Cambiar Investors sold out of Haemonetics (HAE) in Q4 2016, closing a stake of 25,030 shares — an estimated $906K sold.

Cambiar Investors first reported a position in HAE in Q3 2013 and held it in 13 quarters. The position peaked at $43.5M in Q1 2015. 198 funds tracked by Wall St. Rank hold HAE as of Q4 2016.

Cambiar Investors reported no remaining Haemonetics position as of Q4 2016 after selling out during the quarter.
Cambiar Investors sold 25,030 Haemonetics shares in Q4 2016, an estimated $906K.
Cambiar Investors first reported a position in Haemonetics in Q3 2013 and held it in 13 quarters.
Cambiar Investors's Haemonetics position peaked at $43.5M in Q1 2015.
198 funds tracked by Wall St. Rank held Haemonetics as of Q4 2016.

Based on Cambiar Investors's 13F filing for Q4 2016, filed 27 Jan 2017.